The COVID-19 pandemic has reshaped industries—especially healthcare and biopharma. While vaccines provided governments and people in the US and abroad with a new way of fighting the virus, more help is needed. As a significant percentage of the population remains unvaccinated, and new strains of th
The ongoing COVID-19 pandemic has sparked an unprecedented crisis for governments, healthcare providers, and industries across the world. Biopharmaceutical companies were especially affected, as they were left struggling to develop solutions that will ultimately help diagnose and treat those
The Delta variant of the coronavirus has become the dominant strain around the world, bringing with it an increase in deaths in the US and many other countries. While the victims are almost exclusively unvaccinated, the new surge seems to indicate that the COVID-19 pandemic is far from over. The
In 1982, the U.S. approved human insulin—the first ever recombinant biopharmaceutical drug. Since then, biopharma development has proceeded at an exponential pace, with new innovations redefining, over and over again, the possibilities of medicine. Going forward, biopharma will demand more ef
With COVID-19 vaccines becoming more widely available around the world, and countries everywhere easing restrictions, a return to normal is now on everyone’s mind. While many activities are still recovering and regulations remain an important part of our daily lives, optimism is now rising for the f
Biopharmaceuticals are among the most complex and elegant realizations of modern science. But this complexity also comes at great cost. More exactly, biotech-manufacturing facilities need between $200 and $500 million to be built and this process could last up to five years. The Challenges of
